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SUMMARY 
In a cluster-randomised trial, intensive (compared to standard) anthelminthic treatment increased LDL-
cholesterol. In observational analyses schistosome and Strongyloides stercoralis infections were 
associated with reduced serum lipids; heavy schistosome infection with lower blood pressure. Helminth 
elimination may promote cardiovascular disease risk. 
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ABSTRACT 
Background: Helminth infection may influence cardiometabolic risk through effects on inflammation 
and metabolism. We hypothesised that helminths are protective and their treatment detrimental to 
metabolic outcomes. 
Methods: We conducted a cluster-randomised trial in 26 fishing communities, Lake Victoria, Uganda. 
We investigated effects of community-wide intensive (quarterly single-dose praziquantel, triple dose 
albendazole) versus standard (annual single-dose praziquantel, six-monthly single-dose albendazole) 
anthelminthic treatment on metabolic outcomes, and observational associations between helminth 
infection and metabolic outcomes. The primary outcome, homeostatic model assessment of insulin 
resistance (HOMA-IR) and secondary outcomes (including blood pressure, fasting blood glucose and 
lipids) were assessed in a survey conducted after four years of intervention among individuals 10 years. 
Results: We analysed 1898 participants. The intervention had no effect on HOMA-IR (adjusted 
geometric mean ratio [95%CI] 0.96 [0.86,1.07] p=0.42) but resulted in higher mean LDL-cholesterol in 
the intensive arm (2.86 vs 2.60 mmol/L, adjusted mean difference [95%CI] 0.26 [-0.03,0.56] p=0.08). 
Lower LDL-cholesterol levels were observed in S. mansoni (2.37 vs 2.80 mmol/L, -0.25 [-0.49,-0.02] 
p=0.04) and Strongyloides infected (2.34 vs 2.69mmol/L, -0.32 [-0.53,-0.12] p=0.003) participants 
compared with uninfected. S. mansoni infection was associated with lower total cholesterol levels (4.24 
vs 4.64 mmol/L, -0.25 [-0.44,-0.07] p=0.01). Participants with moderate to heavy S. mansoni infection 
had lower triglycerides, LDL-cholesterol and diastolic blood pressure levels. 
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Conclusions: Helminth infections improve lipid profiles and may lower blood pressure. Further studies 
to confirm causality and investigate mechanisms will contribute to understanding the epidemiological 
transition and may suggest new approaches to prevent cardiometabolic disease. 
Clinical trials registration: ISRCTN47196031 
 
KEY WORDS: Helminths; Schistosoma mansoni; Diabetes; Cardiovascular disease; Africa 
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INTRODUCTION 
Non-communicable diseases accounted for 72.3% of deaths globally in 2016 [1]. Ischaemic heart disease 
and cerebrovascular disease are the highest contributors to this mortality and morbidity [1]. Metabolic 
disorders such as type 2 diabetes (T2D) and dyslipidaemia are important cardiovascular disease risk 
factors. In 2017 an estimated 425 million people had diabetes worldwide and the number is projected to 
increase - disproportionately in low and middle income countries (LMIC) - to 629 million by 2045 [2]. 
Dyslipidaemia, which results in atherosclerosis, is the leading risk factor for myocardial infarction [3] and 
stroke [4]. 
Chronic, low-grade, obesity-driven inflammation has been implicated in the aetiology and progression of 
insulin resistance and T2D [5]. Atherosclerosis results from a chronic inflammatory state mediated by 
macrophages in the vascular sub-endothelium combined with high levels of lipids in the systemic 
circulation [6]. Lipids are utilised by and involved in mediation of immune processes; therefore 
inflammation may influence lipid levels in the circulation [7]. Modulation of these inflammatory 
processes may delay the development of T2D and atherosclerosis. 
Over a billion people are helminth-infected worldwide, predominantly in LMIC [8]. Helminths have co-
evolved with humans over millions of years so that they survive in the human host but mostly cause only 
subtle harm. To ensure survival, helminths modify type 2 and regulatory immune responses in the 
human host [9]. With these immunomodulatory properties, helminths may be able to annul the 
inflammation that results in metabolic disorders and therefore confer protection [10]. Studies in 
experimental animals support this hypothesis. Mice infected with Schistosoma mansoni [11], 
Nippostrongylus brasiliensis [12] and Litomosoides sigmodontis [13] had decreased insulin resistance 
and improved glucose tolerance compared to uninfected mice. Infection of mice with S. mansoni 
cercariae [14] and intra-peritoneal inoculation of S. mansoni eggs [15] resulted in lower blood lipid levels 
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than in uninfected/un-inoculated controls. In mice, S. mansoni infection also reduced development of 
atherosclerotic lesions [14] and ES-62, a product from the filarial nematode Acanthocheilonema vitae, 
caused a 60% reduction in aortic atherosclerotic lesions [16]. 
In humans, published studies investigating the effect of helminths on metabolic outcomes are few and 
observational, except for a single trial. In China, history of Schistosoma japonicum infection was 
associated with lower levels of fasting blood glucose, glycated haemoglobin (HbA1c) and insulin 
resistance, and lower prevalence of diabetes and metabolic syndrome [17], while chronic infection with 
this helminth was associated with lower serum triglycerides and total cholesterol [18]. Among Australian 
Aboriginals, Strongyloides stercoralis infection was associated with a lower likelihood of diabetes [19] 
and treatment of Strongyloides worsened glycaemic status [20]. Among the Tsimane of the Bolivian 
Amazon, helminth infection was inversely associated with serum lipid levels [21]. Chronic infection with 
the trematode Opisthorcis felineus was associated with lower serum cholesterol levels and diminished 
atherosclerosis in a post-mortem study in Russia [22]. In Indonesia, infection with soil-transmitted 
helminths (STH) was associated with lower insulin resistance and body mass index (BMI) [23]. The only 
trial to date, conducted in Indonesia, showed no effect of albendazole treatment for STH on insulin 
resistance, BMI or waist circumference overall, but increased insulin resistance in individuals infected 
with STH at baseline [24]. 
Observational studies cannot demonstrate causality and are prone to bias from unmeasured 
confounders. The only previous trial was done in a setting with high prevalence of STH. However, other 
parasitic infections such as S. mansoni, may have a different impact on metabolic outcomes because of 
the different location of adult worms and inflammatory and regulatory elements of their life cycles. We 
therefore aimed to investigate, in a high S. mansoni prevalence setting, the effect of helminths and their 
treatment on metabolic outcomes in individuals aged 10 years. We also conducted observational 
analyses to assess cross-sectional associations between helminths and metabolic outcomes. 
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METHODS 
Study setting and design 
This was a two-arm cluster-randomised trial of community-wide intensive versus standard anthelminthic 
treatment conducted in 26 Lake Victoria fishing villages of Koome sub-county, Mukono district, Uganda 
(ISRCTN47196031). This population is ethnically diverse with the majority from central Uganda (of Bantu 
ethnic origin). There is some acculturation as different ethnic groups live together and use Luganda as 
the lingua franca. The main economic activity is fishing with a minority involved in agriculture. Villages 
are well defined, geographically separate and close to the lake. The residents live in temporary housing 
made from wood (locally obtained) and roofed with iron sheets or plastic. Houses are built close 
together. The island communities trade with mainland communities (both nearby and far) in fish and 
general merchandise. 
The protocol has been published [25]. Briefly, 13 villages were randomised to intensive and 13 to 
standard intervention. Intensive treatment comprised praziquantel 40mg/kg single-dose administered 
using an extended height pole (which extended treatment to include pre-school age-groups) and 
albendazole 400mg triple-dose, both quarterly. Standard treatment comprised single-dose praziquantel 
(40mg/kg) annually and single-dose albendazole (400mg) bi-annually. Trial interventions started in 
September 2012. Originally, the trial was designed to investigate the effects of three years’ intervention 
on allergy-related outcomes and helminth-related morbidity but interventions were extended for an 
extra year allowing us to assess their impact on metabolic outcomes.   
Randomisation and masking 
This was an open trial. Villages were randomised in a 1:1 ratio using restricted randomisation to ensure 
balance for village size, previous community-wide anthelminthic treatment and distance from the sub-
county health centre [25]. 
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Exposures and outcomes 
The exposures of interest were anthelminthic intervention (for the trial) and helminth infections (for 
observational analyses). The primary outcome was insulin resistance measured by the homeostatic 
model assessment of insulin resistance (HOMA-IR) [26], calculated as (fasting serum insulin (U/ml) x 
fasting glucose (mmol/L)) / 22.5. Secondary outcomes were fasting blood glucose, glycated haemoglobin 
(HbA1c), fasting serum lipids (triglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol), blood 
pressure, body mass index (BMI), waist circumference and waist-hip ratio; and (for the trial) helminth 
infection status. 
Procedures 
The effects of helminths and anthelminthic intervention were assessed in a household survey conducted 
in all study villages after four years of intervention. We selected 70 households per village by simple 
random sampling using STATA (College Station Texas, US) (Supplementary methods). Permission for 
household participation was sought from each household head or another adult in the household if the 
head was absent. Household members aged ≥10 years were invited to participate. 
After obtaining written informed consent from each household member (and assent from individuals 
aged 10-17 years), a questionnaire was administered. Data were collected on socio-demographic 
characteristics, diet, exercise, lifestyle, personal and family history of diabetes and hypertension. 
Participants’ blood pressure (BP), weight, height, waist and hip circumference were measured using 
standardised procedures (Supplementary methods). Peripheral venous blood was collected after an 
overnight fast for measurement of the primary and secondary outcomes (Supplementary methods).  
Each participant was requested to provide one stool sample, from which duplicate slides were made and 
examined independently by two experienced technicians using the Kato Katz method. Stool real-time 
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polymerase chain reaction (PCR) was also used to detect S. mansoni, hookworm (Necator Americanus) 
and Strongyloides Stercoralis infection (Supplementary methods).  
Statistical methods 
For this survey, we planned to recruit 1950 participants (Supplementary methods). Statistical analyses 
were done using STATA v13; all analyses allowed for within-cluster correlations. The trial analysis was by 
intention-to-treat and measured cluster-level differences. For continuous outcomes, means were 
calculated for each village (cluster-specific means) and the mean of these within each study arm was 
used as a summary measure of the outcome in that study arm. T-tests were used to compare cluster-
specific means between arms, with corresponding 95% confidence intervals computed. Continuous 
outcomes with skewed cluster-specific mean distributions were log-transformed before analysis and 
results back-transformed to give geometric mean ratios. For binary outcomes we calculated risk ratios 
by dividing the mean of the cluster-specific proportions in the intensive arm by that in the standard arm. 
P-values were calculated from t-tests comparing cluster-specific proportions, and confidence intervals 
using a Taylor series approximation to estimate standard errors. For all outcomes, the effects of the 
intervention were additionally adjusted for age and sex using a two-stage approach [27]. 
The individual level observational analysis was performed to assess helminths as risk factors for 
metabolic disease. Potential confounders were identified based on a causal diagram (supplementary 
figure 1). Crude and adjusted associations were estimated using linear regression models fitted for each 
worm separately. Stata “svy” commands were used to allow for clustering of participants within villages, 
and for the non-self-weighting survey design due to variable village sizes. For adjusted analyses, only risk 
factors/ confounders crudely associated with the outcome with p-value≤0.15 were included in final 
models. No corrections were made for multiple testing. 
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Ethical considerations 
Ethical clearance was granted by Uganda Virus Research Institute Research Ethics Committee (reference 
GC/127/17/01/573), London School of Hygiene and Tropical Medicine (reference 9917) and Uganda 
National Council for Science and Technology (reference HS 2185). Permission to conduct the work was 
granted by community leaders in all study villages. 
RESULTS 
Between April and November 2017, 70 households were randomly selected from each village except in 
two villages with fewer households where all were selected. Of eligible households and eligible 
individuals in those households, 71.3% (1276/1790) and 87.0% (1898/2181) agreed to participate 
respectively. We examined 1817/1898 (95.7%) participants and 88.8% (1686/1898) provided blood 
samples after an overnight fast. Numbers of participants providing data were balanced across trial arms 
(figure 1). 
Characteristics of participants are shown in table 1. This is a young population with mean age 31.5 years 
(SD 11) considering that individuals <10 years were excluded. There are more males than females and 
the main occupation is fishing; the majority (69%;1309/1898) reported daily contact with the lake. 
Activity levels were high: 48.4% (920/1898) reported vigorous physical activity at least weekly, with 
mean number of days 2.8 (SD 2.7). Diet mainly consists of fish (eaten on average 4.8 days a week) and is 
low in fruit (on average one day a week). The majority of participants (64.2%; 1218/1898) reported 
having lived in the village in which they were surveyed throughout the four-year intervention period. 
Only 14.9% (283/1898) had ever undergone BP measurement and 4.2% (80/1898) had previously had 
blood sugar levels tested. 
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Participants living in intensive anthelminthic intervention villages had lower S. mansoni prevalence than 
those in standard intervention villages (stool Kato Katz, intensive 21.9%, standard 35.6%, p=0.02; stool 
PCR, intensive 37.3%, standard 56.0%, p=0.01). Similar effects were observed for hookworm (stool PCR, 
intensive 2.3%, standard 4.8%, p=0.03) and Strongyloides (stool PCR, intensive 4.8%, standard 9.0% 
p=0.02). Around half of S. mansoni infections were of light intensity (intensive 12.2%, standard 17.4%). 
The intervention had no effect on Trichuris trichiura (table 2). 
 
There was no evidence of a difference in HOMA-IR between the study arms (table 3). However, there 
was some evidence of a difference in mean LDL-cholesterol, higher in the intensive arm (2.86 versus 
2.60mmol/l, adjusted mean difference [95% CI] 0.26 [-0.03,0.56] p=0.08). No differences were seen 
between trial arms for the other metabolic parameters (table 3). Further analysis of the metabolic 
outcomes categorised as binary (diabetes, impaired fasting glucose, hypertension, obesity and 
metabolic syndrome) showed no differences between trial arms (supplementary table 1). 
 
Key associations from our observational analysis are shown in table 4; all associations tested are shown 
in supplementary table 2. S. mansoni-infected participants had lower total cholesterol levels than 
uninfected participants (4.24mmol/L vs 4.64mmol/L, crude mean difference [95%] -0.40 [-0.62,-0.19] 
p=0.001).  Strong evidence for this association remained after adjusting for age, sex, occupation, 
residence, diet, exercise, family history of obesity, paternal and maternal tribe (-0.25 [-0.44 -0.07] 
p=0.01). S. mansoni infection was associated with lower LDL-cholesterol (2.37 vs 2.80mmol/L, -0.25 [-
0.49,-0.02] p=0.04) but not with HDL-cholesterol. Strongyloides infection was associated with lower LDL-
cholesterol levels (p=0.003). Participants with heavy S. mansoni infection intensity had lowest 
triglyceride levels (p=0.0004) and lowest diastolic BP (p=0.01). Participants with moderate S. mansoni 
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infection intensity had lowest LDL-cholesterol levels (p=0.04). Co-infection with multiple (increasing) 
helminth species was associated with lower total and LDL-cholesterol (trend p=0.02). 
Four serious adverse events (SAEs) were reported in the first three years of the anthelminthic 
intervention [28]. In the fourth year of the intervention, no SAEs were reported. 
DISCUSSION 
This is the first trial to investigate effects of an anthelminthic intervention on metabolic outcomes in an 
S. mansoni endemic, high-transmission, setting. We found no effect of four years of intensive versus 
standard anthelminthic treatment on insulin resistance, but there a modest increase in LDL-cholesterol 
in the intensive versus standard arm. Consistent with this, there was strong observational evidence of 
association between S mansoni infection and lower levels of total cholesterol and LDL-cholesterol. The 
lowest levels of triglycerides and diastolic blood pressure were observed among participants with heavy 
S. mansoni infection and the lowest levels of LDL-cholesterol among those with moderate S. mansoni 
intensity. Strongyloides infection was also inversely associated with LDL-cholesterol. A dose-response 
relationship was observed between increasing numbers of helminth species detected and lower 
cholesterol levels. 
The effect of the intervention on LDL-cholesterol and consistency of this with our cross-sectional 
observations strongly suggests a causal link between helminth infection and lipid profiles. Our results, in 
a setting dominated by schistosomiasis, accord with findings in experimental animals [14, 29] and with 
associations observed between intestinal nematode infection and lipids in humans [30, 31]. One 
possible mechanism is direct consumption of lipids by helminths. Schistosomes do not synthesise 
cholesterol and rely on the host for their supply [32]. However, the effect of schistosomes is likely not 
limited to direct consumption, with immunological effects implicated. La Flamme et al. showed that 
chronic exposure to S. mansoni eggs reduced serum cholesterol in mice with changes due to egg-
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induced increased uptake of LDL by macrophages [29]. It has been suggested that helminths might 
modulate production of naturally occurring antibodies to cholesterol [33]. Helminths resident in the 
lumen might hinder lipid absorption from the gut directly. In addition, there is evidence that helminth 
infection influences intestinal microbiome [34] which also impacts blood lipids [35]. Studies investigating 
the influence of helminths on the microbiome and how that relates to lipid metabolism would provide a 
deeper understanding of the underlying mechanisms. 
An unanticipated finding was the association between heavy S. mansoni infection intensity and lower 
diastolic BP. Essential hypertension accounts for 90% of hypertension cases. The aetiology is not well 
understood, but it is hypothesised that inflammation may cause essential hypertension [36]. Two 
pathways are proposed. Inflammation of the renal interstitium results in monocyte/macrophage 
infiltration of renal perivascular fat, oxidative stress and loss of peritubular capillaries. This may lead to 
medullary hypoxia, impaired sodium excretion and consequently, hypertension [37]. Secondly, 
inflammation results in monocyte/macrophage infiltration of arterial walls leading to arterial stiffness. 
Arterial stiffness triggers angiotensin II which results in hypertension. Helminths may influence these 
pathways via their immunomodulatory properties. Helminths may also indirectly influence blood 
pressure through effects on the intestinal microbiome. Gut microbiota digest fibre and release short 
chain fatty acids which, on absorption into the circulation stimulate the release of renin, a major 
component of the renin angiotensin aldosterone system [38]. We recommend studies to further explore 
the relationship between helminth infection and BP. 
We were surprised to find no impact of anthelminthic treatment or of helminths on insulin resistance, 
given the strong evidence of effects from animal models and evidence of increased insulin resistance 
following STH treatment among participants in the Indonesian trial. Perhaps the most probable 
explanation lies in the transmission dynamics of schistosomiasis in this transmission “hot-spot” setting; 
and in the biology of schistosomes, as distinct from STH.  In this trial, we observed a reduction in 
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helminth prevalence in the standard arm over time, as well as in the intensive arm [25, 28] and this may 
have weakened any chance of seeing a differential effect of trial interventions on the metabolic 
outcomes. As well, single stool Kato Katz analysis has low sensitivity in detecting S. mansoni infection. As 
previously reported, the more sensitive urine circulating cathodic antigen (CCA) used after three years of 
intervention suggested persistent (albeit reduced intensity) infection in over 80% of participants in both 
trial arms, presumably due to on-going transmission and re-infection. Moreover, schistosomes differ 
from STH in that they reside in the vasculature and treatment does not result in immediate expulsion 
from the body. Immunological changes induced by helminths persist even after treatment of the worms. 
Schistosoma egg antigen elicits reduced insulin resistance in an animal model in the absence of live 
worms, and Schistosoma egg antigen is persistent: liver egg counts were almost unchanged 26 weeks 
after treatment in a mouse model [39]; in humans, antibody to egg antigen was detectable eight years 
after curative treatment of schistosome infection [40]. Therefore, effects of schistosome infection may 
persist after treatment of adult worms with praziquantel. Furthermore, animal models investigating 
effects of helminths on insulin resistance have tended to use obese models. By contrast, fishing 
community populations are generally young, slim and active and therefore at low risk of metabolic 
disorders. 
Our results in this high schistosomiasis transmission setting, namely strong observational associations 
and supportive suggestion of a treatment effect for lipid profiles, contrasting with lack of association or 
treatment effect for insulin resistance, could be explained if the former depends predominantly upon 
active schistosome infection, and the latter upon exposure to schistosome antigen. 
Strengths of our study include the robust trial design, large sample size and intense helminth exposure. 
However, on-going helminth transmission and cluster-level randomisation limited our ability to 
determine effects of helminth elimination and more focused, individually-randomised trials would be 
useful to assess this further. While multiple outcomes were assessed, risking false positive findings, the 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz859/5556806 by London School of H
ygiene & Tropical M
edicine user on 27 Septem
ber 2019
  14 
coherence of results on lipid profiles within the study, and when compared to other studies, is 
persuasive. Finally, we cannot rule out a direct effect of praziquantel and albendazole on metabolic 
outcomes, although no prior evidence suggests this. 
Taken together, our findings have important implications. They provide an understanding on how 
anthelminthic treatment may impact metabolic health, thus increasing the burden of non-
communicable diseases and accelerating the epidemiological transition. Helminth infections may be 
beneficial to lipid metabolism and BP control in humans. Identification of potentially protective 
interactions and the underlying mechanisms is important for the development of future therapies. 
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Table 1: Characteristics of participants aged 10 years enrolled in the survey on metabolic outcomes 
in the Lake Victoria Island Intervention Study on Worms and Allergy-related diseases (LaVIISWA) 
cluster-randomised trial 
Cluster-level characteristics Study arm 
Household-level characteristics Intensive  Standard arm 
Household size (median, IQR)  2 (1-3) 2 (1-3) 
Individual-level characteristics (N=964)  (N=934) 
Sex, male 516 (53.5%) 494 (52.9%) 
Age in years (mean, SD) 32 (11.0) 31 (11.0) 
Age in years, grouped   
 
10-19 105 (10.9%) 110 (11.8%) 
 
20-29 324 (33.6%) 324 (34.7%) 
 
30-39 311 (32.3%) 283 (30.3%) 
 
40+ 224 (23.2%) 217 (23.2%) 
Occupation   
 Child/student 50 (5.2%) 71 (7.6%) 
 Housewife 103 (10.7%) 96 (10.3%) 
 Fishing or lake related 366 (38.0%) 365 (39.1%) 
 Shops, salons, artisans, service providers 68 (7.1%) 95 (10.2%) 
 Bars, restaurants, food providers, entertainment 70 (7.3%) 86 (9.2%) 
 Agriculture, lumbering, charcoal 225 (23.3%) 167 (17.8%) 
 Professional 20 (2.1%) 11 (1.2%) 
 Unemployed 18 (1.9%) 18 (1.9%) 
 Other 44 (4.6%) 25 (2.7%) 
Residence   
Always lived in the village 84 (8.7%) 80 (8.6%) 
Has lived only in the village throughout the intervention period 526 (54.6%) 528 (56.3%) 
Has lived elsewhere in the sub-county during the intervention period 32 (3.2%) 41 (4.4%) 
Lived outside the study area during the intervention period 322 (33.4%) 285 (30.5%) 
Place of birth (if participant has not always lived in the village)   
 
Fishing village 28 (2.9%) 24 (2.6%) 
 
Other rural village 757 (78.5%) 743 (79.6%) 
 
Town 76 (7.9%) 65 (7.0%) 
 
City 19 (2.0%) 22 (2.4%) 
First five years (if participant has not always lived in the village) (mv,13)   
 This village 4 (0.4%) 8 (0.8%) 
 A fishing village 27 (2.8%) 24 (2.6%) 
 Other rural village 747 (77.5%) 733 (78.5%) 
 Town 78 (8.1%) 66 (7.1%) 
 City 19 (2.0%) 22 (2.4%) 
Age of participant when he/she moved to this village (mean, SD) 24 (11.2) 23 (11.3) 
Maternal tribe (grouped by region)  
 
 
Central 342 (35.5%) 336 (36.0%) 
 
Western 156 (16.3%) 138 (14.8%) 
 
Eastern 215 (22.3%) 190 (20.3%) 
 
Northern 90 (9.3%) 112 (12.0%) 
 
Non-Ugandan 157 (16.3%) 154 (16.5%) 
Do not know 4 (0.4%) 4 (0.4%) 
Paternal tribe (grouped by region)  
 
 
Central 387 (40.2%) 364 (39.0%) 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz859/5556806 by London School of H
ygiene & Tropical M
edicine user on 27 Septem
ber 2019
  23 
 
Western 165 (17.1%) 163 (17.5%) 
 
Eastern 213 (22.1%) 172 (18.4%) 
 
Northern 93 (9.7%) 108 (11.6%) 
 
Non-Ugandan 105 (10.9%) 125 (13.4%) 
Do not know 1 (0.1%) 2 (0.2%) 
Self-reported treatment for worms   
Ever treated for worms 866 (89.8%) 795 (85.1%) 
Number of times treated with albendazole in the last 12 months (mean, SD) 1 (0.8) 2 (1.4) 
Number of times treated with albendazole in the last 4 years (mean, SD) 8 (5.4) 4 (2.8) 
Number of times treated with praziquantel in the last 12 months (mean, SD) 2 (1.4) 0.5 (0.6) 
Number of times treated with praziquantel in the last 4 years (mean, SD) 8 (5.4) 2 (1.6) 
Frequency of lake contact (mv, 41)   
 Every day 630 (65.3%) 679 (72.7%) 
 Almost every day 161 (16.7%) 136 (14.6%) 
 Once a week 120 (12.5%) 72 (7.7%) 
 Once a month 33 (3.4%) 19 (2.0%) 
 Less than once a month 3 (0.3%) 4 (0.4%) 
Ever had blood sugar measured (mv, 30)   
 Yes 43 (4.5%) 37 (4.0%) 
 No 905 (93.8%) 879 (94.1%) 
 Do not know 2 (0.2%) 2 (0.2%) 
Blood sugar measured in the past 12 months   
 Yes 18 (1.9%) 13 (1.4%) 
 No 26 (2.7%) 25 (2.7%) 
History of diabetes (mv, 30)   
 Yes 4 (0.4%) 3 (0.3%) 
 No 932 (96.7%) 909 (97.3%) 
 Do not know 14 (1.5%) 6 (0.6%) 
Ever had blood pressure measured (mv, 30)   
 Yes 147 (15.3%) 136 (14.6%) 
 No 802 (83.2%) 782 (83.4%) 
 Do not know 1 (0.1%) 0 
Blood pressure measured in the past 12 months (mv, 30)   
 Yes 66 (6.9%) 61 (6.5%) 
 No 81 (8.4%) 75 (8.0%) 
History of hypertension (mv, 30)   
 Yes 20 (2.1%) 24 (2.6%) 
 No 925 (96.0%) 890 (95.3%) 
 Do not know 5 (0.5%) 4 (0.4%) 
Frequency of exercise / participation in vigorous physical activity (mv, 30)   
 Every day 19 (2.0%) 8 (0.9%) 
 Almost every day 193 (20.5%) 194 (21.2%) 
 Once a week 305 (32.5%) 177 (19.3%) 
 Once a month 305 (18.3%) 187 (20.4%) 
 Less than once a month 237 (25.2%) 333 (36.4%) 
Number of days in a week a participant performs vigorous physical activity 
(mean SD) 
3.0 (2.7) 2.6 (2.7) 
Hours spent per day performing vigorous physical activity (mean, SD) 3.4 (3.4) 2.9 (3.4) 
Diet (in a typical week) (mv, 30)   
 Number of days you eat fruit (mean, SD) 1.0 (1.5) 0.8 (1.4) 
 Number of servings of fruit you eat on one of those days (mean, SD) 0.5 (0.7) 0.4 (0.7) 
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 Number of days you eat vegetables (mean, SD) 0.8 (1.3) 0.4 (1.0) 
 Number of days you eat fish (mean, SD) 4.8 (2.3) 4.8 (2.2) 
 Number of days you eat meat (mean, SD) 0.3 (0.9) 0.4 (1.1) 
Type of oil or fat that is most often used for meal preparation in the 
household or where the participant eats (mv, 30) 
 
 
 Vegetable oil 845 (87.7%) 794 (85.0%) 
 Other oils 14 (1.5%) 10 (1.1%) 
 None in particular 23 (2.4%) 13 (1.4%) 
 None used 54 (5.6%) 78 (8.3%) 
 Don’t know 14 (1.5) 23 (2.5%) 
Ever smoked (either pipe or cigarette) (mv, 30)   
 Yes 175 (18.2%) 168 (18.0%) 
 No 775 (80.4%) 750 (80.3%) 
Currently smoking tobacco products daily 147 (15.3%) 128 (13.7%) 
Ever taken alcohol (mv, 30)  482 (50.0%) 423 (45.3%) 
Currently drinking alcohol 406 (42.1%) 352 (37.7%) 
Maternal history of diabetes (mv, 30)  
        No history 801 (83.1%) 764 (81.8%) 
       History of diabetes 30 (3.1%) 39 (4.2%) 
 
Do not know 119 (12.3%) 115 (12.3%) 
Paternal history of diabetes (mv, 30)   
 No history 785 (81.4%) 790 (84.6%) 
 History of diabetes 28 (2.9%) 25 (2.7%) 
 Don't know 137 (14.2%) 103 (11.0%) 
Maternal history of hypertension (mv, 30)   
       No history 688 (71.3%) 669 (71.6%) 
       History of hypertension 148 (15.4%) 137 (14.7%) 
 Don't know 114 (11.8%) 112 (12.0%) 
Paternal history of hypertension (mv, 30)   
 No history 764 (79.3%) 775 (83.0%) 
 History of hypertension 52 (5.4%) 40 (4.3%) 
 Don't know 134 (1.5%) 103 (11.0%) 
Maternal history of obesity/ overweight (mv, 30)   
       No history 811 (84.1%) 774 (82.9%) 
       History of obesity/ overweight 14 (1.5%) 14 (1.5%) 
 Don't know 125 (13.0%) 130 (13.9%) 
Paternal history of obesity/ overweight (mv, 30)   
       No history 805 (83.5%) 803 (86.0%) 
       History of obesity/ overweight 4 (0.4%) 8 (0.9%) 
 Don't know 141 (14.6%) 107 (11.5%) 
mv, missing values; SD, Standard deviation 
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Table 2: Effect of intensive versus standard anthelminthic treatment on helminth prevalence in the metabolic survey of the Lake Victoria Island 
Intervention Study on Worms and Allergy-related diseases (LaVIISWA) cluster-randomised trial (cluster-level analysis) (n=1853) 
Outcome 
 
% Crude 
risk ratio (95% CI) 
 
P-value 
*Adjusted 
risk ratio (95% CI) 
*P-value 
Intensive arm Standard arm 
Schistosoma mansoni, stool Kato Katz 21.9 35.6 0.62 (0.41, 0.92) 0.02 0.71 (0.54, 0.93) 0.02 
Schistosoma mansoni, stool PCR 37.3 56.0 0.67 (0.51, 0.89) 0.007 0.76 (0.63, 0.94) 0.01 
S. mansoni intensity 
stool Kato Katz 
Light 12.2 17.4     
Moderate 4.9 11.4     
Heavy 4.8 6.8     
Trichuris trichiura, stool Kato Katz 7.4 8.1 0.91 (0.41, 2.02) 0.82 0.78 (0.36, 1.68) 0.50 
Hookworm, stool PCR 2.3 4.8 0.47 (0.22, 1.01) 0.03 0.48 (0.23, 1.01) 0.03 
Strongyloides stercoralis, stool PCR 4.8 9.0 0.54 (0.34, 0.86) 0.01 0.52 (0.31, 0.87) 0.02 
CI, Confidence intervals; *Adjusted for age, sex and baseline helminth prevalence **Baseline prevalence measured using stool PCR  
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Table 3: Effect of intensive versus standard anthelminthic treatment on metabolic outcomes in the metabolic survey of the Lake Victoria Island 
Intervention Study on Worms and Allergy-related diseases (LaVIISWA) cluster-randomised trial (cluster-level analysis) (n=1853) 
Outcome mean Crude mean 
difference/geometric mean 
ratio (95% CI) 
P-value Adjusted mean 
difference/geometric mean ratio 
(95% CI)* 
P-value* 
Intensive  Standard 
HOMA – IR (glucose x insulin/22.5) GM 1.24** GM 1.30** GMR 0.96 (0.85, 1.07)*** 0.43 aGMR 0.96 (0.86, 1.07)*** 0.42 
Fasting glucose (mmol/L) 4.78 4.76 0.02 (-0.16, 0.20) 0.85 0.01 (-0.17, 0.19) 0.90 
Glycated haemoglobin (mmol/m) 30.72 30.56 0.16 (-2.09, 2.41) 0.88 0.14 (-2.11, 2.40) 0.90 
Triglycerides (mmol/L) GM 0.98** GM 0.98** GMR 1.00 (0.94, 1.06)*** 0.95 aGMR 0.97 (0.85, 1.11)*** 0.63 
Total cholesterol (mmol/L) 4.52 4.33 0.19 (-0.16, 0.54)  0.27 0.19 (-0.16, 0.54) 0.28 
LDL – Cholesterol (mmol/L) 2.86 2.60 0.27 (-0.03, 0.56) 0.08 0.26 (-0.03, 0.56) 0.08 
HDL – Cholesterol (mmol/L) GM 1.20** GM 1.20** GMR 1.01 (0.87, 1.17)*** 0.94 aGMR 1.01 (0.87, 1.17)*** 0.94 
Systolic blood pressure (mmHg) 115.27 116.13 -0.86 (-2.84, 1.12) 0.38 -1.02 (-2.72, 0.68) 0.22 
Diastolic blood pressure (mmHg) 76.40 76.37 0.03 (-1.25, 1.31) 0.97 -0.12 (-1.34, 1.10) 0.84 
Body mass index (kg/m2) 23.34 23.34 0.01 (-0.50, 0.51) 0.99 -0.08 (-0.58, 0.42) 0.74 
Waist circumference (cm) 80.00 80.04 -0.04 (-1.49, 1.41) 0.95 -0.32 (-1.70, 1.07) 0.64 
Waist-hip Ratio 0.85 0.85 0.00 (0.00, 0.01) 0.96 0.00 (-0.01, 0.00) 0.72 
CI, Confidence intervals; GM, Geometric mean; GMR, Geometric mean ratio; aGMR, adjusted geometric mean ratio; *Adjusted for age and sex; **Geometric 
means used because of skewed cluster-specific means; *** Geometric mean ratios used because of skewed cluster-specific means 
 
 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz859/5556806 by London School of H
ygiene & Tropical M
edicine user on 27 Septem
ber 2019
  27 
Table 4: Associations between helminth infection and metabolic outcomes 
  Mean Crude mean difference  
  (95% CI)* 
P value Adjusted mean difference 
 (95% CI)** 
P value** 
HOMA-IR       
S. mansoni, stool Kato Katz    Uninfected (n=1065) GM 1.90      
 Infected (n=440) GM 1.69 -0.05 (-0.12, 0.02) 0.12 0.05 (-0.05, 0.15) 0.28 
S. mansoni, stool PCR Uninfected (n=793) GM 1.62     
 Infected (n=694) GM 2.06 -0.10 (-0.21, 0.01) 0.07 -0.01 (-0.08, 0.06) 0.77 
S. mansoni intensity, stool Kato Katz    Uninfected (n=1065) GM 1.90      
 Light (n=230) GM 2.07 0.04 (-0.09, 0.17)  0.09 ( -0.07, 0.25)   
 Moderate (n=121) GM 1.20 -0.20 (-0.35, -0.05)  -0.04 (-0.19, 0.12)   
 Heavy (n=89) GM 1.61 -0.07 (-0.21, 0.06) 0.07 0.07 (-0.11, 0.25) 0.69 
T. trichiura, stool Kato Katz    Uninfected (n=1383) GM 1.82      
 Infected (n=122) GM 2.00 0.04 (-0.08 0.17) 0.50 0.08 (-0.05, 0.20) 0.21 
Hookworm, stool PCR Uninfected (n=1309) GM 1.83     
 Infected (n=55) GM 1.76 -0.02 (-0.17, 0.14) 0.83 0.11 (-0.18, 0 .40) 0.45 
Strongyloides stercoralis stool PCR Uninfected (n=1385) GM 1.89     
 Infected (n=101) GM 1.25 -0.18 (-0.40, 0.035) 0.10 0.04 (-0.16, 0.24) 0.70 
Infection with multiple helminth species (S. 
mansoni [PCR], T. trichiura, Hookworm and S. 
stercoralis) 
Helminth uninfected 
(n=655) GM 2.12     
Infected with any one GM 1.58 -0.13 (-0.23, -0.03)  -0.04 (-0.12, 0.04)  
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helminth (n=611) 
 Infected with any two 
helminths (n=155) GM 1.90 -0.05 (-0.18, 0.09)  0.13 (0.03, 0.23)  
 Infected with any three or 
four helminths (n=17) GM 1.11 -0.28 (-0.58, 0.02) <0.01 -0.22 (-0.66, 0.23) 0.05 
Infection with multiple helminth species 
(testing for trend)   -0.07 (-0.12, -0.02) 0.01 0.01 (-0.04, 0.06) 0.61 
Triglycerides (mmol/L)       
S. mansoni, stool Kato Katz         Uninfected (n=1065) GM 1.02      
 Infected (n=440) GM 0.90 -0.05 (-0.12, 0.01) 0.12 -0.05 (-0.14, 0.03) 0.21 
S. mansoni, stool PCR Uninfected (n=793) GM 1.00     
 Infected (n=694) GM 0.95 -0.02 (-0.07, 0.02) 0.28 -0.04 (-0.08, 0.01) 0.09 
S. mansoni intensity, stool Kato Katz    Uninfected (n=1065) GM 1.02      
 Light (n=230) GM 0.95 -0.03 (-0.15, 0.08)   -0.05 (-0.18, 0.08)   
 Moderate (n=121) GM 0.98 -0.02 (-0.11, 0.08)  0.00 (-0.09, 0.09)   
 Heavy (n=89) GM 0.72 -0.15 (-0.23, -0.08) <0.01 -0.13 (-0.20, -0.07) <0.01 
T. trichiura, stool Kato Katz    Uninfected (n=1383) GM 0.99      
 Infected (n=122) GM 0.87 -0.06 (-0.11, -0.00) 0.04 -0.05 ( -0.13, 0.04) 0.29 
Hookworm, stool PCR Uninfected (n=1309) GM 0.97     
 Infected (n=55) GM 0.67 -0.17 (-0.30, -0.03) 0.02 -0.08 (-0.25, 0.09) 0.32 
Strongyloides stercoralis, stool PCR Uninfected (n=1385) GM 0.97     
 Infected (n=101) GM 0.95 -0.01 (-0.09, 0.08) 0.84 -0.05 (-0.15, 0.05) 0.32 
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Infection with multiple helminth species (S. 
mansoni [PCR], T. trichiura, Hookworm and S. 
stercoralis) 
Helminth uninfected 
(n=655) GM 0.99     
Infected with any one 
helminth (n=611) GM 0.97 -0.01 (-0.04, 0.03)  -0.01 (-0.05, 0.02)  
 Infected with any two 
helminths (n=155) GM 0.87 -0.05 (-0.12, 0.01)  -0.07 (-0.15, 0.02)  
 Infected with any three or 
four helminths (n=17) GM 0.65 -0.18 (-0.37, 0.01) 0.23 -0.20 (-0.49, 0.09) 0.50 
Infection with multiple helminth species 
(testing for trend)   -0.03 (-0.05, 0.00) 0.06 -0.03 (-0.07, 0.01) 0.12 
Total cholesterol (mmol/L)       
S. mansoni, stool Kato Katz         Uninfected (n=1065) 4.64      
 Infected (n=440) 4.24 -0.40 (-0.62, -0.19) <0.01 -0.25 (-0.44, -0.07) 0.01 
S. mansoni, stool PCR Uninfected (n=793) 4.69     
 Infected (n=694) 4.32 -0.37 (-0.63, -0.11) 0.007 -0.28 (-0.53, -0.03) 0.03 
S. mansoni intensity, stool Kato Katz    Uninfected (n=1065) 4.64      
 Light (n=230) 4.34 -0.30 (-0.54, -0.07)  -0.19 (-0.42, 0.05)   
 Moderate (n=121) 4.17 -0.48 ( -0.77, -0.19)  -0.33 (-0.59, -0.08)   
 Heavy (n=89) 4.10 -0.55 (-0.87, -0.23) 0.01 -0.33 (-0.62, -0.04) 0.06 
T. trichiura, stool Kato Katz    Uninfected (n=1383) 4.53      
 Infected (n=122) 4.39 -0.14 (-0.42, 0.15) 0.33 0.00 (-0.25, 0.24) 0.99 
Hookworm, stool PCR Uninfected (n=1309) 4.53     
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 Infected (n=55) 4.06 -0.47 (-0.76, -0.18) 0.003 -0.22 (-0.53, 0.09) 0.16 
Strongyloides stercoralis, stool PCR Uninfected (n=1385) 4.53     
 Infected (n=101) 4.24 -0.29 (-0.61, 0.03) 0.07 -0.22 (-0.53, 0.08) 0.15 
Infection with multiple helminth species (S. 
mansoni [PCR], T. trichiura, Hookworm and S. 
stercoralis) 
Helminth uninfected 
(n=655) 4.71     
Infected with any one 
helminth (n=611) 4.37 -0.34 (-0.62, -0.06)  -0.27 (-0.53, -0.01)  
 Infected with any two 
helminths (n=155) 4.23 -0.48 (-0.83, -0.13)  -0.32 (-0.63, -0.01)  
 Infected with any three or 
four helminths (n=17) 3.75 -0.97 (-1.49, -0.44) 0.01 -0.53 (-1.08, 0.02) 0.11 
Infection with multiple helminth species 
(testing for trend)   -0.29 (-0.48, -0.09) <0.01 -0.20 (-0.36, -0.03) 0.02 
LDL – Cholesterol (mmol/L)       
S. mansoni, stool Kato Katz         Uninfected (n=1065) 2.80      
 Infected (n=440) 2.37 -0.43 (-0.74, -0.12) 0.01  -0.25 ( -0.49, -0.02) 0.04 
S. mansoni, stool PCR Uninfected (n=793) 2.87     
 Infected (n=694) 2.45 -0.42 (-0.78, -0.05) 0.03 -0.28 (-0.57, 0.01) 0.06 
S. mansoni intensity, stool Kato Katz    Uninfected (n=1065) 2.80      
 Light (n=230) 2.49  -0.32 (-0.60, -0.03)  -0.23 (-0.46, 0.00)   
 Moderate (n=121) 2.18 -0.62 (-0.97, -0.28)  -0.39 (-0.72, -0.05)   
 Heavy (n=89) 2.34  -0.46 (-0.91, -0.01) <0.01 -0.14 ( -0.51, 0.23) 0.04 
T. trichiura, stool Kato Katz    Uninfected (n=1383) 2.66      
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 Infected (n=122) 2.69 0.03 (-0.32, 0.37) 0.87 0.05 (-0.22, 0.33) 0.7 
Hookworm, stool PCR Uninfected (n=1309) 2.67     
 Infected (n=55) 2.13 -0.55 (-0.79, -0.30) <0.01 0.08 (-0.19, 0.35) 0.55 
Strongyloides stercoralis, stool PCR Uninfected (n=1385) 2.69     
 Infected (n=101) 2.34 -0.35 (-0.58, -0.12) 0.004 -0.32 (-0.53, -0.12) 0.003 
Infection with multiple helminth species (S. 
mansoni [PCR], T. trichiura, Hookworm and S. 
stercoralis) 
Helminth uninfected 
(n=655) 2.90     
Infected with any one 
helminth (n=611) 2.48 -0.42 (-0.82, -0.02)  -0.27 (-0.55, 0.02)  
 Infected with any two 
helminths (n=155) 2.44 -0.46 (-0.78, -0.13)  -0.29 (-0.54, -0.05)  
 Infected with any three or 
four helminths (n=17) 1.96 -0.94 (-1.57, -0.31) 0.02 -0.52 (-1.14, 0.10) 0.10 
Infection with multiple helminth species 
(testing for trend)   -0.30 (-0.53, -0.07) 0.01 -0.19 (-0.35, -0.04) 0.02 
HDL – Cholesterol (mmol/L)       
S. mansoni, stool Kato Katz    Uninfected (n=1065) GM 1.81      
 Infected (n=440) GM 1.82 0.09 (-0.14, 0.14) 0.98 0.05 (-0.04, 0.14) 0.26 
S. mansoni, stool PCR Uninfected (n=793) GM 1.83     
 Infected (n=694) GM 1.79 -0.01 (-0.16, 0.14) 0.92 0.00 (-0.09, 0.09) 0.96 
S. mansoni intensity, stool Kato Katz    Uninfected (n=1065) GM 1.81      
 Light (n=230) GM 1.80 -0.01 (-0.10, 0.09)  0.06 (-0.03, 0.14)   
 Moderate (n=121) GM 2.19 0.08 (-0.08, 0.24)  0.12 (-0.01, 0.26)   
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 Heavy (n=89) GM 1.49 -0.08 (-0.34, 0.17) 0.02 -0.07 (-0.22, 0.09) 0.07 
T. trichiura, stool Kato Katz    Uninfected (n=1383) GM 1.83      
 Infected (n=122) GM 1.62 -0.06 (-0.18, 0.07) 0.38 0.00 (-0.12, 0.12) 0.97 
Hookworm, stool PCR Uninfected (n=1309) GM 1.84     
 Infected (n=55) GM 2.02 0.04 (-0.18, 0.26) 0.70 -0.03 (-0.13, 0.08) 0.57 
Strongyloides stercoralis, stool PCR Uninfected (n=1385) GM 1.81     
 Infected (n=101) GM 1.79 -0.01 (-0.10, 0.09) 0.92 -0.04 (-0.13, 0.05) 0.36 
Infection with multiple helminth species (S. 
mansoni [PCR], T. trichiura, Hookworm and S. 
stercoralis) 
Helminth uninfected 
(n=655) GM 1.82     
Infected with any one 
helminth (n=611) GM 1.83 0.00 (-0.16, 0.17)  0.00 (-0.10, 0.10)  
 Infected with any two 
helminths (n=155) GM 1.70 -0.03 (-0.16, 0.11)  -0.02 (-0.11, 0.07)  
 Infected with any three or 
four helminths (n=17) GM 1.75 -0.02 (-0.24, 0.21) 0.86 0.05 (-0.19, 0.28) 0.89 
Infection with multiple helminth species 
(testing for trend)   -0.01 (-0.10, 0.09) 0.88 -0.00 (-0.06, 0.05) 0.89 
Diastolic blood pressure (mmHg)       
S. mansoni, stool Kato Katz         Uninfected (n=1065) 76.30      
 Infected (n=440) 75.86 -0.44 (-1.89, 1.01) 0.54 0.72 (-1.40, 2.84) 0.49 
S. mansoni, stool PCR Uninfected (n=793) 76.35     
 Infected (n=694) 75.88 -0.46 (-1.48, 0.56) 0.36 0.56 (-0.84, 1.95) 0.42 
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S. mansoni intensity, stool Kato Katz    Uninfected (n=1065) 76.30      
 Light (n=230) 76.58 0.27 (-1.08, 1.63)  1.25 (-0.71, 3.22)   
 Moderate (n=121) 76.75 0.45 (-2.56, 3.47)  1.55 (-2.35, 5.46)   
 Heavy (n=89) 72.84 -3.46 (-4.81, -2.12) <0.01 -2.29 (-3.91, -0.68) 0.01 
T. trichiura, stool Kato Katz    Uninfected (n=1383) 76.40      
 Infected (n=122) 72.97 -3.43 (-5.64, -1.22) <0.01 -1.45 (-3.58, 0.69) 0.18 
Hookworm, stool PCR Uninfected (n=1309) 76.35     
 Infected (n=55) 72.44 -3.90 (-7.22, -0.59) 0.02 2.20 (-0.92, 5.33) 0.16 
Strongyloides stercoralis, stool PCR Uninfected (n=1385) 76.09     
 Infected (n=101) 76.60 0.51 (-2.67, 3.69) 0.74 -0.56 (-3.25, 2.14) 0.68 
Infection with multiple helminth species (S. 
mansoni [PCR], T. trichiura, Hookworm and S. 
stercoralis) 
Helminth uninfected 
(n=655) 76.44     
Infected with any one 
helminth (n=611) 76.34 -0.10 (-1.22, 1.02)  0.87 (-0.80, 2.53)  
 Infected with any two 
helminths (n=155) 74.07 -2.37 (-4.33, -0.41)  0.08 (-2.21, 2.38)  
 Infected with any three or 
four helminths (n=17) 70.78 -5.66 (-12.24, 0.91) 0.10 -4.11 (-10.33, 2.11) 0.47 
Infection with multiple helminth species 
(testing for trend)   -0.94 (-1.70, -0.18) 0.02 -0.26 (-1.13, 0.61) 0.54 
CI, Confidence intervals; GM, Geometric mean; PCR, Polymerase chain reaction; *Both crude and adjusted results allowed for the survey design i.e. weighting 
and clustering. **Adjusted for the following variables: HOMA-IR (age, sex, occupation, residence, lake contact, treatment for worms, treatment with 
coartem, BMI, family history of DM, maternal and paternal tribe); Triglycerides (age, sex, occupation, residence, diet,  treatment for worms, family history of 
obesity, paternal and maternal tribe); Total cholesterol (age, sex, occupation, residence, diet, exercise, family history of obesity, paternal and maternal 
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tribe); LDL – Cholesterol (age, sex, occupation, diet, exercise, treatment for worms, treatment with coartem, parental tribe ); HDL – Cholesterol (age, sex, 
occupation, residence, diet, treatment for worms, treatment with coartem, parental tribe); Diastolic blood pressure (age, sex, occupation, residence, lake 
contact, treatment for worms, paternal tribe, BMI); There was no evidence of association between helminth infection and fasting blood glucose, glycated 
haemoglobin, systolic blood pressure, body mass index, waist circumference and waist-hip ratio (shown in supplementary table 2)  
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FIGURE 
Title: Figure 1: Flow chart of the survey on metabolic outcomes in the Lake Victoria Island Intervention Study on Worms and Allergy-related diseases 
(LaVIISWA) cluster-randomised trial 
Legend: 
* In two villages, the total number of households per village was less than 70 and therefore all households (41 and 69 respectively) were invited to 
participate 
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